Literature DB >> 22474109

Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression.

Nian Liu1, Zhipeng Meng, Guiyu Lou, Weiping Zhou, Xiaoqiong Wang, Yunfeng Zhang, Lisheng Zhang, Xiyong Liu, Yun Yen, Lily Lai, Barry M Forman, Zhonggao Xu, Rongzhen Xu, Wendong Huang.   

Abstract

Farnesoid X receptor (FXR) (nuclear receptor subfamily 1, group H, member 4) is a member of nuclear hormone receptor superfamily, which plays essential roles in metabolism of bile acids, lipid, and glucose. We previously showed spontaneously hepatocarcinogenesis in aged FXR(-/-) mice, but its relevance to human hepatocellular carcinoma (HCC) is unclear. Here, we report a systematical analysis of hepatocarcinogenesis in FXR(-/-) mice and FXR expression in human liver cancer. In this study, liver tissues obtained from FXR(-/-) and wild-type mice at different ages were compared by microarray gene profiling, histological staining, chemical analysis, and quantitative real-time PCR. Primary hepatic stellate cells and primary hepatocytes isolated from FXR(-/-) and wild-type mice were also analyzed and compared. The results showed that the altered genes in FXR(-/-) livers were mainly related to metabolism, inflammation, and fibrosis, which suggest that hepatocarcinogenesis in FXR(-/-) mice recapitulated the progression of human liver cancer. Indeed, FXR expression in human HCC was down-regulated compared with normal liver tissues. Furthermore, the proinflammatory cytokines, which were up-regulated in human HCC microenvironment, decreased FXR expression by inhibiting the transactivity of hepatic nuclear factor 1α on FXR gene promoter. Our study thereby demonstrates that the down-regulation of FXR has an important role in human hepatocarcinogenesis and FXR(-/-) mice provide a unique animal model for HCC study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474109      PMCID: PMC3355555          DOI: 10.1210/me.2011-1383

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  35 in total

1.  Conditional hepatocarcinogenesis in mice expressing SV 40 early sequences.

Authors:  Dan-Qing Lou; Thierry Molina; Myriam Bennoun; Arlette Porteu; Pascale Briand; Virginie Joulin; Mireille Vasseur-Cognet; Catherine Cavard
Journal:  Cancer Lett       Date:  2005-11-08       Impact factor: 8.679

2.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.

Authors:  Insook Kim; Keiichirou Morimura; Yatrik Shah; Qian Yang; Jerrold M Ward; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

3.  The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma.

Authors:  Brian C Lewis; David S Klimstra; Nicholas D Socci; Su Xu; Jason A Koutcher; Harold E Varmus
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

4.  Benefit of farnesoid X receptor inhibition in obstructive cholestasis.

Authors:  Catherine Stedman; Christopher Liddle; Sally Coulter; Junichiro Sonoda; Jacqueline G Alvarez; Ronald M Evans; Michael Downes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-14       Impact factor: 11.205

Review 5.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

6.  Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration.

Authors:  Wendong Huang; Ke Ma; Jun Zhang; Mohammed Qatanani; James Cuvillier; Jun Liu; Bingning Dong; Xiongfei Huang; David D Moore
Journal:  Science       Date:  2006-04-14       Impact factor: 47.728

7.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.

Authors:  Fan Yang; Xiongfei Huang; Tangsheng Yi; Yun Yen; David D Moore; Wendong Huang
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 8.  Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.

Authors:  Ahmed M Elsharkawy; Derek A Mann
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

9.  Functional analysis on the 5'-flanking region of human FXR gene in HepG2 cells.

Authors:  Guiyu Lou; Yuping Li; Bin Chen; Min Chen; Jian Chen; Rongxia Liao; Yan Zhang; Yuangzhon Wang; Dujin Zhou
Journal:  Gene       Date:  2007-04-18       Impact factor: 3.688

10.  Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3.

Authors:  Kimberly J Riehle; Jean S Campbell; Ryan S McMahan; Melissa M Johnson; Richard P Beyer; Theo K Bammler; Nelson Fausto
Journal:  J Exp Med       Date:  2007-12-24       Impact factor: 14.307

View more
  45 in total

1.  Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice.

Authors:  Zhipeng Meng; Xiaoqiong Wang; Yichao Gan; Yunfeng Zhang; Hong Zhou; Carl Van Ness; Jun Wu; Guiyu Lou; Hua Yu; Chao He; Rongzhen Xu; Wendong Huang
Journal:  J Hepatol       Date:  2012-06-21       Impact factor: 25.083

2.  Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment.

Authors:  Prasant K Jena; Lili Sheng; Hui-Xin Liu; Karen M Kalanetra; Annie Mirsoian; William J Murphy; Samuel W French; Viswanathan V Krishnan; David A Mills; Yu-Jui Yvonne Wan
Journal:  Am J Pathol       Date:  2017-07-12       Impact factor: 4.307

3.  S-allyl-cysteine attenuates carbon tetrachloride-induced liver fibrosis in rats by targeting STAT3/SMAD3 pathway.

Authors:  Zhiqiang Gong; Huisheng Ye; Yu Huo; Lei Wang; Yanhong Huang; Min Huang; Xingxing Yuan
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

4.  Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models.

Authors:  Prasant Kumar Jena; Lili Sheng; Nidhi Nagar; Chao Wu; Daniela Barile; David A Mills; Yui-Jui Yvonne Wan
Journal:  J Nutr Biochem       Date:  2018-04-25       Impact factor: 6.048

Review 5.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 6.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 7.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

Review 8.  Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.

Authors:  Vineet K Dhiman; Michael J Bolt; Kevin P White
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

Review 9.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

10.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.